Clinical Trials In Kentucky
Discover hundreds of clinical trials in Kentucky.
Search clinical trials in Kentucky by city, condition or phase.
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Sponsor:
AstraZeneca
Location:
Code:
NCT06120491
Conditions
Metastatic Castration-Sensitive Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Saruparib
Placebo
Abiraterone Acetate
Darolutamide
Enzalutamide
Zimmer Biomet Shoulder Arthroplasty PMCF
Sponsor:
Zimmer Biomet
Location:
Code:
NCT04984291
Conditions
Shoulder Fractures
Shoulder Arthritis
Shoulder Osteoarthritis
Shoulder Deformity
Shoulder Injuries
Eligibility Criteria
Sex: All
Age: 20+
Healthy Volunteers: Not accepted
Interventions
Alliance Glenoid
Identity Stem
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT06126276
Conditions
Malignant Female Reproductive System Neoplasm
Malignant Solid Neoplasm
Recurrent Malignant Female Reproductive System Neoplasm
Recurrent Malignant Solid Neoplasm
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biopsy
Biospecimen Collection
Computed Tomography
Echocardiography
Magnetic Resonance Imaging
Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Sponsor:
RayzeBio, Inc.
Location:
Code:
NCT05477576
Conditions
GEP-NET
Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor Disease
Neuroendocrine Tumors
Carcinoid
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RYZ101
Everolimus
Sunitinib
Octreotide
Lanreotide
Endovascular Therapy for Low NIHSS Ischemic Strokes
Sponsor:
Emory University
Location:
Code:
NCT04167527
Conditions
Cerebral Ischemia
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Immediate mechanical thrombectomy(iMT) using EmboTrap Revascularization Device
Initial medical management (iMM)
Product Surveillance Registry
Sponsor:
Medtronic
Location:
Code:
NCT01524276
Conditions
Cardiac Rhythm Disorders
Urological Disorders
Neurological Disorders
Cardiovascular Disorders
Digestive Disorders
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
Sponsor:
Takeda
Location:
Code:
NCT06550076
Conditions
Plaque Psoriasis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TAK-279
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Sponsor:
Inhibrx Biosciences, Inc
Location:
Code:
NCT06295731
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
INBRX-106
Pembrolizumab
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT03866382
Conditions
Bladder Adenocarcinoma
Bladder Clear Cell Adenocarcinoma
Bladder Mixed Adenocarcinoma
Bladder Neuroendocrine Carcinoma
Bladder Small Cell Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT05147220
Conditions
Relapsing Multiple Sclerosis
Eligibility Criteria
Sex: All
Age: 18 - 55
Healthy Volunteers: Not accepted
Interventions
Remibrutinib
Teriflunomide